Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

NCT06799026 is registered in ClinicalTrials.gov with David Avigan as lead sponsor.

NCT NCT06799026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06799026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
Lead sponsor
David Avigan
Phase
Phase 1
Overall status
Recruiting
Start date
January 31, 2025
Completion date
September 1, 2030
Enrollment
25 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, refractory multiple myeloma, relapse multiple myeloma